How Does Cannabis Affect Hormones and the Endocrine System?

Cannabis can interact with hormonal regulation, but its effects are not a predictable rise or fall in every hormone. Human findings vary by the cannabinoid, dose, timing, frequency of use, and population studied. A change in a laboratory measurement also does not automatically mean an endocrine disease, infertility, or a therapeutic benefit.

The endocrine system includes glands that regulate stress responses, reproduction, growth, and metabolism. The body’s endocannabinoid signaling system interacts with some of these pathways. THC and CBD have different pharmacology, so evidence about one cannot simply be transferred to the other. Neither should be regarded as a general hormone-balancing treatment.

Cortisol and the Stress Response

In controlled laboratory studies of intravenous THC, cortisol rose in a dose-related fashion. Frequent cannabis users had a smaller response than controls. This helps explain why acute exposure and repeated use may produce different findings, but intravenous THC is not equivalent to a typical edible or smoked product.

A smaller cortisol response does not establish healthier stress regulation, and feeling relaxed does not demonstrate that an abnormal hormone level has been corrected. An endocrine diagnosis requires clinical assessment rather than an inference from the immediate effects of cannabis.

Testosterone: The Evidence Is Mixed

The American Society for Reproductive Medicine review describes inconsistent associations between cannabis and male reproductive hormones. Some early studies reported lower testosterone, while later studies found higher levels or no clear difference. Differences in exposure, timing, and the people studied make a universal claim inappropriate.

A 2026 study of 47 young male cannabis users and 47 controls found higher levels of several androgens among users, including testosterone. It was a cross-sectional comparison, not a trial showing that starting cannabis raises testosterone. It also did not establish improved fertility or a reason to use cannabis for low testosterone.

A hormone concentration is only one part of reproductive health. Symptoms, repeated clinically indicated measurements, and other potential causes matter more than applying an average from a research group to an individual.

Menstrual Cycles and Fertility

ASRM found no consistent association with most female reproductive hormones examined. Evidence on ovulation, time to pregnancy, semen parameters, and assisted-reproduction outcomes is also inconsistent. That uncertainty should not be rewritten as either guaranteed infertility or proven safety.

ASRM advises informing people about recommendations to reduce or stop marijuana use during preconception and pregnancy. If you are trying to conceive, discuss use with the fertility or obstetric team. New menstrual changes should be evaluated rather than automatically attributed to cannabis.

Thyroid Tests Are Not Evidence of Thyroid Treatment

A 2017 analysis of 5,280 adults found that recent marijuana use was associated with lower thyroid-stimulating hormone (TSH), but not with thyroid dysfunction. The study used survey and laboratory data collected at one point in time; it did not test cannabis as a treatment for hypothyroidism or autoimmune thyroid disease.

TSH helps clinicians interpret thyroid function together with other results and symptoms. Lowering a marker is not necessarily beneficial, and this finding does not justify replacing thyroid medicine with THC or CBD.

Diabetes and Metabolic Claims

Evidence about the endocannabinoid system’s role in metabolism is not proof that retail cannabis treats diabetes. In a 13-week pilot trial involving 62 adults with type 2 diabetes, participants received CBD, THCV, combinations, or placebo. The fasting-glucose signal favored THCV, a different cannabinoid. Reported CBD changes in two metabolic markers were significant against baseline, not against placebo.

The trial’s primary HDL-cholesterol endpoint was not improved by THCV. These exploratory results should not be presented as proof that CBD controls blood sugar or that a commercial cannabis product can replace diabetes treatment.

Observational reports of lower weight in cannabis users have similar limits. A 2024 CARDIA analysis found lower BMI with current use but no association with cumulative use, with residual confounding a likely explanation. Cannabis is not an established treatment for metabolic syndrome.

What a Recent CBD Trial Adds

A 2025 FDA-led randomized trial tested CBD at 2.5 mg/kg twice daily for 28 days in healthy adults. It found no significant between-group differences in the measured endocrine outcomes, which included testosterone, inhibin B, and thyroid hormones.

That is a limited short-term finding, not evidence that CBD has no possible endocrine effects or is safe in pregnancy. The same study found liver enzyme elevations above three times the upper limit of normal in 5.6% of CBD recipients and none receiving placebo. Those elevations were asymptomatic and resolved after stopping.

Discuss Symptoms and Products With a Clinician

If you have persistent fatigue, menstrual changes, sexual symptoms, fertility concerns, or an abnormal hormone test, seek an assessment of the underlying cause. Tell the clinician the product, THC and CBD amounts, frequency, and timing of recent use, along with all medicines and supplements.

Do not change prescribed thyroid, diabetes, fertility, or other hormone treatment based on a cannabis study. The useful question is whether a specific exposure could affect your symptoms, test interpretation, or medicines—not whether cannabis universally raises, lowers, or balances hormones.